Not a good buy right now for an impatient entry: price is sitting on/just below key support (S1 ~8.081) with weak-to-neutral momentum and no proprietary buy signals today.
Options are pricing very high near-term uncertainty (30D IV ~163.8, IV percentile ~87.7), which typically means the market expects big moves; without a clear upside catalyst this favors waiting rather than chasing.
Insider selling has surged (+178% over the last month), which is a notable near-term sentiment headwind.
Wall Street remains broadly constructive (mostly Buy/Overweight with high targets), but the stock is not currently showing an “urgent buy-now” setup on the tape.
Technical Analysis
Trend/Momentum: MACD histogram is negative (-0.00621) but contracting (downtrend pressure easing, not reversed).
RSI(6) ~31.5: near oversold territory, suggesting a bounce is possible, but it’s not a confirmed reversal signal.
Moving averages: converging, consistent with consolidation/indecision rather than a clean uptrend.
Key levels: current ~8.06 is right at S1 (8.081). A sustained hold above S1 can spark a technical bounce; a break risks a move toward S2 (7.808). Upside resistance sits at Pivot 8.522, then R1 8.963.
Positioning: Open interest put/call at 0.37 is notably call-heavy (bullish positioning bias).
Flow: Volume put/call ~0.85 is closer to balanced (not a strong bullish “chase” today).
Volatility: 30D IV ~163.8 vs historical vol ~64.6; IV percentile ~87.7 indicates options are very expensive and the market is pricing a large move (often around catalysts like earnings).
Activity: today’s options volume is far below recent averages (148 vs ~2.6k–2.9k 5–10D avg), suggesting no strong fresh conviction flow this session so far.
Technical Summary
Sell
11
Buy
2
Positive Catalysts
with momentum, a technical bounce toward ~8.96 becomes more plausible.
on 2026-02-25 pre-market can act as a volatility catalyst if guidance/launch metrics surprise positively.
Neutral/Negative Catalysts
Heavy insider selling trend (selling amount up ~178% over the last month) is a clear near-term bearish sentiment signal.
Price is precariously near support (S1 8.081); a breakdown could accelerate to S2 (7.808).
No supportive news flow in the last week; lack of fresh catalysts increases the odds the stock follows broader risk-off tape (S&P pre-market -0.7%).
Options imply very high event risk (extreme IV); if results/updates are merely “ok,” the stock can still sell off into/after the event.
Financial Performance
Latest reported quarter: 2025/Q3.
Revenue: $20.75M, flat YoY (0.00% YoY) — not showing strong growth acceleration in the reported snapshot.
Profitability: Net loss improved to -$74.116M (loss narrowed 36.23% YoY), and EPS improved to -0.85 (34.92% YoY improvement), indicating cost/expense trajectory is moving in the right direction.
Gross margin: 100% (unchanged), consistent with the nature of reported revenue (but not enough detail here to confirm durability/scale).
Growth
Profitability
Efficiency
Analyst Ratings and Price Target Trends
Recent change: BofA (2026-02-03) trimmed PT slightly to $29 from $30, maintained Buy — a minor reset rather than a thesis break.
Prior trend (Nov 2025): multiple firms raised targets materially and reiterated bullish ratings (Barclays to $28 from $11 Overweight; Wedbush to $38 Outperform; UBS to $16 Buy; BofA to $30 Buy) following ziftomenib approval.
Wall Street pros: regulatory milestone achieved and meaningful upside to targets if launch/commercial traction materializes.
Wall Street cons: near-term earnings may be less impactful amid pre-announcements; execution/launch metrics likely matter more than the print, and the stock can remain volatile while the story transitions from approval to commercialization.
Wall Street analysts forecast KURA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for KURA is 29.71 USD with a low forecast of 16 USD and a high forecast of 40 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
10 Analyst Rating
Wall Street analysts forecast KURA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for KURA is 29.71 USD with a low forecast of 16 USD and a high forecast of 40 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
9 Buy
1 Hold
0 Sell
Strong Buy
Current: 7.400
Low
16
Averages
29.71
High
40
Current: 7.400
Low
16
Averages
29.71
High
40
BofA
Jason Zemansky
Buy
downgrade
$30 -> $29
AI Analysis
2026-02-03
Reason
BofA
Jason Zemansky
Price Target
$30 -> $29
AI Analysis
2026-02-03
downgrade
Buy
Reason
BofA analyst Jason Zemansky lowered the firm's price target on Kura Oncology to $29 from $30 and keeps a Buy rating on the shares. Given the level of pre-announcements, upcoming Q4 earnings "may not have the same impact they've had in prior years," the analyst tells investors in a preview for the firm's biopharma coverage.
Barclays
Etzer Darout
Overweight
maintain
$11 -> $28
2025-11-24
Reason
Barclays
Etzer Darout
Price Target
$11 -> $28
2025-11-24
maintain
Overweight
Reason
Barclays analyst Etzer Darout raised the firm's price target on Kura Oncology to $28 from $11 and keeps an Overweight rating on the shares. The firm cites the ziftomenib approval for the target increase.
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for KURA